Evidence map›Paper›PMID 35016920›Full record

ReviewPharmacology & therapeutics2022

The immune modifying effects of chemotherapy and advances in chemo-immunotherapy.

Daniel R Principe, Suneel D Kamath, Murray Korc, Hidayatullah G Munshi

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Chemoimmunotherapy synergism: mechanisms and clinical applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Daniel R PrincipeMedical Scientist Training Program, University of Illinois College of Medicine, Chicago, IL, USA; Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: principe@illinois.edu.
Suneel D KamathCleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Murray KorcDepartment of Developmental and Cell Biology, University of California, Irvine, CA, USA.
Hidayatullah G MunshiFeinberg School of Medicine, Northwestern University, Chicago, IL, USA; Jesse Brown VA Medical Center, Chicago, IL, USA.
Cleveland Clinic · USIllinois College · USNorthwestern University · USUniversity of California, Irvine · US

Funding

Novel aspects of Epithelial-Mesenchymal Transition(EMT)in pancreatic cancerR01CA075059 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI KORC, MURRAY · 1997 to 2018
$4.3M
Galpha13 and pancreatic cancer progressionR01CA217907 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MUNSHI, HIDAYATULLAH G. · 2018 to 2022
$1.8M
Rapid evaluation of immunotherapy regimens in ex vivo human pancreatic tumor slice cultures.R21CA255291 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MUNSHI, HIDAYATULLAH G. · 2021 to 2022
$406k
Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway InhibitionF30CA236031 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PRINCIPE, DANIEL R · 2019 to 2023
$256k
Targeting MNK Pathways in Pancreatic CancerI01BX002922 · VA · JESSE BROWN VA MEDICAL CENTER · PI MUNSHI, HIDAYATULLAH G. · 2017 to 2020
–
BLRD VA I01 BX002922NCI NIH HHS F30 CA236031NCI NIH HHS R01 CA075059NCI NIH HHS R01 CA217907NCI NIH HHS R21 CA255291
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for several malignancies. While the use of single-agent or combined ICIs has achieved acceptable disease control rates in a variety of solid tumors, such approaches have yet to show substantial therapeutic efficacy in select difficult-to-treat cancer types. Recently, select chemotherapy regimens are emerging as extensive modifiers of the tumor microenvironment, leading to the reprogramming of local immune responses. Accordingly, data is now emerging to suggest that certain anti-neoplastic agents modulate various immune cell processes, most notably the cross-presentation of tumor antigens, leukocyte trafficking, and cytokine biosynthesis. As such, the combination of ICIs and cytotoxic chemotherapy are beginning to show promise in many cancers that have long been considered poorly responsive to ICI-based immunotherapy. Here, we discuss past and present attempts to advance chemo-immunotherapy in these difficult-to-treat cancer histologies, mechanisms through which select chemotherapies modify tumor immunogenicity, as well as important considerations when designing such approaches to maximize efficacy and improve therapeutic response rates.

Indexed as

Antineoplastic AgentsNeoplasmsAntigens, NeoplasmHumansImmunologic FactorsImmunotherapyTumor MicroenvironmentAntigens, NeoplasmAntineoplastic AgentsImmunologic FactorsCancerChemotherapyImmune checkpoint inhibitorsImmunologyTumor microenvironment

Identifiers

PMID35016920
PMCPMC9271143
OpenAlexW4205524463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.